Cipla has received US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all 3 strengths—100/50 mcg, 250/50 mcg, and 500/50 mcg.

The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

According to IQVIA, the US market for fluticasone propionate and salmeterol inhalation powder is approximately USD 908 million. This approval represents Cipla's first Dry Powder Inhaler (DPI) approval from its US-based manufacturing network, marking a significant milestone in the company's continued expansion of complex respiratory capabilities in the US.

Commenting on the approval, Achin Gupta, Managing Director (MD) and Global CEO, Cipla, said, "At Cipla, we're passionate about respiratory care given our long-standing expertise. This approval reinforces our commitment to expanding access to complex therapies in the US and highlights our strength in developing and scaling sophisticated inhalation products through integrated capabilities."

Backed by Cipla's vertically integrated inhalation platform, the product reflects the company's commitment to strengthening US manufacturing capabilities for complex respiratory treatments.

Marc Falkin, Chief Executive Officer (CEO), Cipla North America, added, "This approval marks our first dry powder inhaler from our New York facility and reflects our targeted investments in building differentiated inhalation manufacturing capabilities in the US. It strengthens our ability to provide reliable, high-quality supply in an important and competitive category."